Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 31Gastrointestinal 31Genitourinary 3Thoracic 2Head & Neck 1Breast 1

Conditions

Thyroid Neoplasms 7Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Renal Cell 3Breast Neoplasms 3Adenocarcinoma, Follicular 3Salivary Gland Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Nervous System Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma 1

Interventions

trastuzumab deruxtecan 1trametinib 1spartalizumab 1ribociclib 1pexidartinib 1pembrolizumab 1dabrafenib 1Thalidomide 1Sunitinib 1Specimen Handling 1OSI 930 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Cetuximab 1Capecitabine 1CTLA-4 Antigen 17-hydroxystaurosporine 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Sunitinib × Head & Neck × Clear all
NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡